Although our results confirmed that common amyloid and tau CSF biomarkers help diagnose AD even at early stages, more interestingly, hypocretin-1 is significantly and independently associated with this group of patients, with an OR of 2.70 after full adjustment. This evidence concerns the gene MAPT and Alzheimer disease.